| Year |
Citation |
Score |
| 2020 |
Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernández FM, Nephew KP, Karpf AR, ... ... Sood AK, et al. Targeting progesterone signaling prevents metastatic ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 33262282 DOI: 10.1073/pnas.2013595117 |
0.317 |
|
| 2020 |
Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. PMID 33149280 DOI: 10.1038/s41388-020-01517-3 |
0.31 |
|
| 2020 |
Wen Y, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, Bartsch F, Redfern L, Zand B, Kang Y, Liu J, Baggerly K, Sood AK. Blockade of the short-form of prolactin receptor induces FOXO3a/EIF-4EBP1-mediated cell death in uterine cancer. Molecular Cancer Therapeutics. PMID 32737156 DOI: 10.1158/1535-7163.Mct-19-1026 |
0.333 |
|
| 2019 |
Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK. Clinical and biological significance of expression in endometrial cancer. Cancer Biology & Therapy. 1-10. PMID 31640461 DOI: 10.1080/15384047.2019.1672455 |
0.315 |
|
| 2019 |
Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ. Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology. 106: 244-251. PMID 31005045 DOI: 10.1016/J.Psyneuen.2019.04.007 |
0.312 |
|
| 2019 |
Yokoi A, Villar-Prados A, Oliphint PA, O'Halloran TJ, Roszik J, Sood AK. Abstract LB-232: A novel approach for liquid biopsy by using nExo Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-232 |
0.308 |
|
| 2018 |
An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene. PMID 30455428 DOI: 10.1038/S41388-018-0565-9 |
0.304 |
|
| 2018 |
Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, ... ... Sood AK, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications. 9: 2923. PMID 30050129 DOI: 10.1038/S41467-018-04987-Y |
0.317 |
|
| 2018 |
Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 30036226 DOI: 10.1097/Igc.0000000000001329 |
0.306 |
|
| 2018 |
Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. 23: 3170-3182. PMID 29898390 DOI: 10.1016/J.Celrep.2018.05.022 |
0.342 |
|
| 2018 |
Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 9: 25115-25126. PMID 29861857 DOI: 10.18632/Oncotarget.25344 |
0.308 |
|
| 2018 |
Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports. 23: 297-312.e12. PMID 29617668 DOI: 10.1016/J.Celrep.2018.03.064 |
0.303 |
|
| 2018 |
Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley KM, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Research. PMID 29386184 DOI: 10.1158/0008-5472.Can-17-1624 |
0.325 |
|
| 2018 |
Ma S, Pradeep S, Wu S, Kim MS, Hu W, Mangala S, Coleman RL, Sood AK. Abstract 4817: EP-100 sensitizes BRCA wild-type ovarian cancer cells to PARP inhibitor Cancer Research. 78: 4817-4817. DOI: 10.1158/1538-7445.Am2018-4817 |
0.302 |
|
| 2017 |
Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. The Journal of Clinical Investigation. PMID 29251630 DOI: 10.1172/Jci95200 |
0.333 |
|
| 2017 |
Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, ... ... Sood AK, et al. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Molecular Therapy. Nucleic Acids. 9: 251-262. PMID 29246304 DOI: 10.1016/J.Omtn.2017.06.023 |
0.332 |
|
| 2017 |
Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs R, ... ... Sood AK, et al. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Molecular Cancer Therapeutics. PMID 29237804 DOI: 10.1158/1535-7163.Mct-17-0006 |
0.305 |
|
| 2017 |
Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Demarzo A, Sood AK, Zhang L, Dang CV. MYC targeted long non-coding RNA DANCR promotes cancer in part by reducing p21 levels. Cancer Research. PMID 29180471 DOI: 10.1158/0008-5472.Can-17-0815 |
0.301 |
|
| 2017 |
Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, ... ... Sood AK, et al. PRKCI promotes immune suppression in ovarian cancer. Genes & Development. PMID 28698296 DOI: 10.1101/Gad.296640.117 |
0.308 |
|
| 2017 |
Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, ... ... Sood AK, et al. Metastasis regulation by PPARD expression in cancer cells. Jci Insight. 2: e91419. PMID 28097239 DOI: 10.1172/Jci.Insight.91419 |
0.314 |
|
| 2017 |
Ghazaly EA, Quesne JL, Jiang D, Mangala SL, Chettle J, Rodriguez-Aguayo C, Lopez-Berestein G, Gnanaranjan C, Mura M, Stavraka C, Sood AK, Blagden SP. Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-B30 |
0.302 |
|
| 2017 |
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Dorniak PL, ... ... Sood AK, et al. Abstract 4144: Role of CTGF in hyperthermia resistance in ovarian and uterine cancers Cancer Research. 77: 4144-4144. DOI: 10.1158/1538-7445.Am2017-4144 |
0.335 |
|
| 2016 |
Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, ... ... Sood AK, et al. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Research. 76: 6320-6330. PMID 27803105 DOI: 10.1158/0008-5472.Can-16-0854 |
0.307 |
|
| 2016 |
Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Domiak PL, Filant J, Dial EJ, ... ... Sood AK, et al. Anti-tumor and Anti-angiogenic Effects of Aspirin-PC in Ovarian Cancer. Molecular Cancer Therapeutics. PMID 27638860 DOI: 10.1158/1535-7163.Mct-16-0074 |
0.304 |
|
| 2016 |
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nature Reviews. Disease Primers. 2: 16061. PMID 27558151 DOI: 10.1038/nrdp.2016.61 |
0.313 |
|
| 2016 |
Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang W. ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget. PMID 27517494 DOI: 10.18632/oncotarget.11120 |
0.308 |
|
| 2016 |
Bayraktar E, Rodriguez-Aguayo C, Mai J, Ivan C, Chavez-Reyes A, Sood AK, Ferrari M, Shen H, Lopez-Berestein G. Abstract 4668: Silencing PTGER3 enhances chemotherapeutic responses Cancer Research. 76: 4668-4668. DOI: 10.1158/1538-7445.Am2016-4668 |
0.335 |
|
| 2016 |
Wen Y, Sood A. Abstract 3529: Immunotherapy targeting folate receptor induces autophagy in ovarian cancer Cancer Research. 76: 3529-3529. DOI: 10.1158/1538-7445.Am2016-3529 |
0.305 |
|
| 2015 |
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, ... ... Sood AK, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. PMID 26686630 DOI: 10.1016/J.Celrep.2015.11.047 |
0.308 |
|
| 2015 |
Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology. 53: 256-67. PMID 25647344 DOI: 10.1016/J.Psyneuen.2015.01.010 |
0.313 |
|
| 2015 |
Wu SY, Filant J, McGuire M, Rupaimoole R, Pradeep S, Unruh A, Shelley H, Ivan C, Dennis R, Rodriguez-Aguayo C, Sehgal V, Miyake T, Nagaraja A, Gharpure K, Armaiz G, ... ... Sood A, et al. Abstract 5466: Integrative TCGA analyses identify Basonuclin1 (BNC1) as a key mediator for platinum resistance Cancer Research. 75: 5466-5466. DOI: 10.1158/1538-7445.Am2015-5466 |
0.321 |
|
| 2015 |
Leung CS, Yeung T, Yip K, Wong K, Sood AK, Birrer MJ, Mok SC. Abstract 4184: CAF-derived MFAP5 promotes tumor angiogenesis and confers paclitaxel resistance in high-grade serous ovarian cancer Cancer Research. 75: 4184-4184. DOI: 10.1158/1538-7445.Am2015-4184 |
0.358 |
|
| 2015 |
Wen Y, Sood AK. Abstract 3817: Suicidal autophagy induced by immunotherapy targeting folate receptor in ovarian cancer Cancer Research. 75: 3817-3817. DOI: 10.1158/1538-7445.Am2015-3817 |
0.337 |
|
| 2015 |
Liu Y, Choi DS, Grandos-Principal S, Qian W, Burey L, Wong H, Rodriguez-Aguayo C, Sood A, Li Z, Wong S, Weiss H, Dave B, Landis M, Chang JC. Abstract 2312: Identifying novel cancer stem cell target for triple-negative breast cancer Cancer Research. 75: 2312-2312. DOI: 10.1158/1538-7445.Am2015-2312 |
0.318 |
|
| 2015 |
Gharpure KM, Tucker SL, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, ... ... Sood A, et al. Abstract 2273: Mechanistic and functional implications of FABP4 in ovarian cancer metastasis Cancer Research. 75: 2273-2273. DOI: 10.1158/1538-7445.Am2015-2273 |
0.305 |
|
| 2015 |
Yang L, Achreja A, Moss T, Baddour J, Stilles K, Chiba L, Kim SH, Morse J, Marini J, Sood AK, Ram PT, Nagrath D. Abstract 1208: Glutamine modulates cellular NAD+/NADH homeostasis thereby regulating cancer metastasis, drug sensitivity in cancer cells Cancer Research. 75: 1208-1208. DOI: 10.1158/1538-7445.Am2015-1208 |
0.328 |
|
| 2014 |
Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications. 5: 5092. PMID 25277212 DOI: 10.1038/Ncomms6092 |
0.332 |
|
| 2014 |
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, ... ... Sood AK, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 26: 77-91. PMID 25026212 DOI: 10.1016/J.Ccr.2014.05.002 |
0.326 |
|
| 2014 |
Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, et al. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Molecular Oncology. 8: 1429-40. PMID 24974076 DOI: 10.1016/J.Molonc.2014.05.017 |
0.319 |
|
| 2014 |
Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, ... ... Sood AK, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology. 10: 728. PMID 24799285 DOI: 10.1002/Msb.20134892 |
0.314 |
|
| 2014 |
Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, ... ... Sood AK, et al. Notch3 pathway alterations in ovarian cancer. Cancer Research. 74: 3282-93. PMID 24743243 DOI: 10.1158/0008-5472.Can-13-2066 |
0.302 |
|
| 2014 |
Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, ... ... Sood AK, et al. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2740-50. PMID 24634380 DOI: 10.1158/1078-0432.Ccr-13-2507 |
0.309 |
|
| 2014 |
Pradeep S, Kim SW, Wu S, Masato N, Miyake T, Hyun-Jin C, Rupaimoole R, Liu J, Fidler I, Lopez G, Sood A. Abstract 4954: Hematogenous metastasis of ovarian cancer: Re-thinking mode of spread Cancer Research. 74: 4954-4954. DOI: 10.1158/1538-7445.Am2014-4954 |
0.338 |
|
| 2014 |
Chaluvally-Raghavan P, Zhang F, Liu W, Tyler M, Yu S, Pradeep S, Ram P, Lu Y, Sood A, Mills G. Abstract 4396: MicroRNA MIR551B amplified at 3q26.2 locus activate c-KIT expression and causes resistance to anoikis of ovarian cancer cells Cancer Research. 74: 4396-4396. DOI: 10.1158/1538-7445.Am2014-4396 |
0.312 |
|
| 2014 |
Reyes-González JM, Armaiz GN, Mangala LS, Valiyeva F, Pradeep S, Sood AK, Vivas-Mejía PE. Abstract 3761: Nanoliposomal c-MYC-siRNA inhibitsin vivotumor growth of cisplatin-resistant ovarian cancer Cancer Research. 74: 3761-3761. DOI: 10.1158/1538-7445.Am2014-3761 |
0.323 |
|
| 2014 |
Dalton HJ, Reusser NM, Zien A, Jackson D, Previs R, Rupaimoole R, Zand B, Lopez-Berestein G, Coleman RL, Sood AK. Abstract 2983: Bisphosphonates: New strategies for targeting angiogenesis in ovarian cancer Cancer Research. 74: 2983-2983. DOI: 10.1158/1538-7445.Am2014-2983 |
0.333 |
|
| 2014 |
Leung CS, Yeung T, Yip K, Wong K, Sood AK, Birrer MJ, Mok SC. Abstract 1029: CAF-derived MFAP5 promotes ovarian tumor angiogenesis through calcium dependent LPP signaling pathway Cancer Research. 74: 1029-1029. DOI: 10.1158/1538-7445.Am2014-1029 |
0.302 |
|
| 2013 |
Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. Plos One. 8: e79167. PMID 24236104 DOI: 10.1371/Journal.Pone.0079167 |
0.308 |
|
| 2013 |
Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 809-20. PMID 23344261 DOI: 10.1158/1078-0432.Ccr-12-2736 |
0.304 |
|
| 2013 |
Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 170-82. PMID 23147994 DOI: 10.1158/1078-0432.Ccr-12-1045 |
0.304 |
|
| 2013 |
Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK. Neuroendocrine influences on cancer progression. Brain, Behavior, and Immunity. 30: S19-25. PMID 22728325 DOI: 10.1016/J.Bbi.2012.06.005 |
0.308 |
|
| 2013 |
Miyake TM, Pradeep S, Zand B, Dalton HJ, Wen Y, Pena GNA, Kauffman M, McCauley D, Shacham S, Wiktorowicz JE, Sood AK. Abstract 5541: Therapeutic targeting of CRM1 in ovarian cancer. Cancer Research. 73: 5541-5541. DOI: 10.1158/1538-7445.Am2013-5541 |
0.33 |
|
| 2013 |
Wu SY, Unruh AK, Rupaimoole R, Ivan C, Ruder D, Pradeep S, Sehgal V, Rodriguez-Aguayo C, Pecot C, Miyake T, Lopez-Berestein G, Ram P, Baggerly KA, Sood AK. Abstract 2036: Overcoming platinum-resistance in ovarian cancer via targeting basonuclin1 (BNC1). Cancer Research. 73: 2036-2036. DOI: 10.1158/1538-7445.Am2013-2036 |
0.304 |
|
| 2013 |
Saha S, Bhattacharyya S, Giri K, Lanza IR, Nair KS, Jennings NB, Kumar R, Sood AK, Bhattacharya R, Mukherjee P. Abstract 1882: Role of cystathionine beta-synthase in ovarian cancer growth, metastasis and drug sensitivity. Cancer Research. 73: 1882-1882. DOI: 10.1158/1538-7445.Am2013-1882 |
0.317 |
|
| 2013 |
Reyes J, Ivan C, Sood AK, Vivas-Mejia PE. Abstract A52: Targeting c-MYC in cisplatin-resistant ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A52 |
0.307 |
|
| 2012 |
Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biology & Therapy. 13: 1034-41. PMID 22895067 DOI: 10.4161/Cbt.21045 |
0.328 |
|
| 2012 |
Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Current Pharmaceutical Design. 18: 2713-2719. PMID 22390757 DOI: 10.2174/138161212800626201 |
0.339 |
|
| 2012 |
Wu SY, Unruh AK, Bartholomeusz G, Ivan C, Pecot CV, Rupaimoole R, Han H, Bottsford-Miller J, Tucker SL, Coleman RL, Lopez-Berestein G, Baggerly KA, Sood AK. Abstract 884: Basonuclin1 (BNC1): A novel therapeutic target in ovarian cancer identified through integrative TCGA-based functional genomic analysis Cancer Research. 72: 884-884. DOI: 10.1158/1538-7445.Am2012-884 |
0.311 |
|
| 2012 |
Vathipadiekal V, Ozbun L, Lee J, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Mok SC, Birrer MJ. Abstract 5057: Gene expression profile of chemoresponse of microdissected papillary serous tumors of the ovary identifies POLH and REV3L as potential therapeutic targets Cancer Research. 72: 5057-5057. DOI: 10.1158/1538-7445.Am2012-5057 |
0.305 |
|
| 2012 |
Wen Y, Zand B, Yu K, Bottsford-Miller J, Stone RL, Carroll A, Pecot CV, Pradeep S, Wu S, Hu W, Ozpolat B, Coleman R, Sood AK. Abstract 2268: Suicidal tendencies: The promotion of cell death by a prolactin antagonist through autophagy in ovarian cancer Cancer Research. 72: 2268-2268. DOI: 10.1158/1538-7445.Am2012-2268 |
0.336 |
|
| 2011 |
Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, ... ... Sood AK, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. Plos One. 6: e21121. PMID 21754983 DOI: 10.1371/Journal.Pone.0021121 |
0.333 |
|
| 2011 |
Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (New York, N.Y.). 13: 393-405. PMID 21532880 DOI: 10.1593/Neo.101720 |
0.335 |
|
| 2011 |
Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. Plos One. 6: e17918. PMID 21445297 DOI: 10.1371/Journal.Pone.0017918 |
0.328 |
|
| 2011 |
Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2250-9. PMID 21421858 DOI: 10.1158/1078-0432.Ccr-10-2718 |
0.318 |
|
| 2011 |
Matsuo K, Nishimura M, Stone RL, Komurov K, Shahzad MM, Bottsford-Miller JN, Enomoto T, Kimura T, Ram PT, Schmeler KM, Frumovitz M, Gallick GG, Wong KK, Sood AK. Abstract 5032: Targeting Src in mucinous ovarian carcinoma Cancer Research. 71: 5032-5032. DOI: 10.1158/1538-7445.Am2011-5032 |
0.322 |
|
| 2010 |
Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Hormones & Cancer. 1: 277-90. PMID 21761359 DOI: 10.1007/S12672-010-0054-2 |
0.314 |
|
| 2010 |
Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular Cancer Therapeutics. 9: 3186-99. PMID 20889728 DOI: 10.1158/1535-7163.Mct-10-0563 |
0.301 |
|
| 2010 |
Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. The Journal of Clinical Investigation. 120: 1515-23. PMID 20389021 DOI: 10.1172/Jci40802 |
0.308 |
|
| 2010 |
Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opinion On Biological Therapy. 10: 431-437. PMID 20092424 DOI: 10.1517/14712591003592069 |
0.307 |
|
| 2010 |
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, ... ... Sood AK, et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 184-94. PMID 20028751 DOI: 10.1158/1078-0432.Ccr-09-1180 |
0.342 |
|
| 2010 |
Fu S, Li Y, Shen D, Zheng H, Kavanagh JJ, Bast RC, Sood AK, Hu W. Abstract 670: Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3 Cancer Research. 70: 670-670. DOI: 10.1158/1538-7445.Am10-670 |
0.324 |
|
| 2010 |
Rodriguez-Aguayo C, Vivas-Mejia P, Benito JM, Fernandez A, Francois-Xavier C, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Abstract 5468: JNK-1 inhibition leads to antitumor activity in ovarian cancer Cancer Research. 70: 5468-5468. DOI: 10.1158/1538-7445.Am10-5468 |
0.344 |
|
| 2010 |
Landen CN, Goodman B, Nick AM, Stone RL, Meijia PV, Miller LD, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer Cancer Research. 70: 4288-4288. DOI: 10.1158/1538-7445.Am10-4288 |
0.326 |
|
| 2010 |
Chakravarty D, Challa R, Dandamudi R, Vivas-Mejia P, Lopez-Berestein G, Tekmal RR, Sood AK, Vadlamudi RK. Abstract 3669: PELP1: A novel therapeutic target for ovarian cancer progression and metastasis Cancer Research. 70: 3669-3669. DOI: 10.1158/1538-7445.Am10-3669 |
0.355 |
|
| 2008 |
Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Research. 68: 5849-58. PMID 18632639 DOI: 10.1158/0008-5472.Can-07-6130 |
0.305 |
|
| 2008 |
Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK. EphA2 overexpression promotes ovarian cancer growth. Cancer Biology & Therapy. 7: 1098-103. PMID 18443431 DOI: 10.4161/Cbt.7.7.6168 |
0.317 |
|
| 2008 |
Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. American Journal of Obstetrics and Gynecology. 198: 477.e1-9; discussion. PMID 18395047 DOI: 10.1016/J.Ajog.2007.12.028 |
0.301 |
|
| 2006 |
Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, ... ... Sood AK, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Journal of the National Cancer Institute. 98: 1558-70. PMID 17077358 DOI: 10.1093/Jnci/Djj414 |
0.311 |
|
| 2005 |
Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opinion On Therapeutic Targets. 9: 1179-87. PMID 16300469 DOI: 10.1517/14728222.9.6.1179 |
0.314 |
|
| 2004 |
Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. The American Journal of Pathology. 165: 1087-95. PMID 15466376 DOI: 10.1016/S0002-9440(10)63370-6 |
0.317 |
|
| 1998 |
Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ. Field cancerization: why late "recurrent" ovarian cancer is not recurrent. American Journal of Obstetrics and Gynecology. 178: 641-649. PMID 9579425 DOI: 10.1016/S0002-9378(98)70473-9 |
0.32 |
|
| Show low-probability matches. |